Mesoblast WKN: A0DNPW ISIN: AU000000MSB8 Kürzel: LWB Branche: Gesundheit, Biotechnologie
|
Themen zum Wert | ||
---|---|---|---|
1 | MESOBLAST Hauptdiskussion |
Kursdetails
Geld (bid) | 0,00 (0) |
---|---|
Brief (ask/offer) | 0,00 (0) |
Spread | - |
Geh. Stück | 694 Tsd. |
Eröffnung | 0,34 |
Vortag | 0,19 |
Tageshoch | 0,47 |
Tagestief | 0,34 |
52W Hoch | 1,00 |
52W Tief | 0,10 |
Tagesvolumen
in EUR gehandelt | 107 Tsd. Stk |
---|---|
in USD gehandelt | 694 Tsd. Stk |
in CHF gehandelt | 1.000 Stk |
in AUD gehandelt | 0 Stk |
Gesamt | 803 Tsd. Stk |
Partner-News
AnzeigeGestern 18:00 Uhr • Partner • Societe Generale
Gestern 16:46 Uhr • Partner • Societe Generale
Gestern 16:00 Uhr • Partner • BNP Paribas
Gestern 15:00 Uhr • Partner • HSBC
Gestern 14:35 Uhr • Partner • Societe Generale
Aktien-News
Gestern 22:42 Uhr • Meldungen • IRW-News
Gestern 19:33 Uhr • Artikel • dpa-AFX
Gestern 18:26 Uhr • Partner • shareribs
Gestern 18:04 Uhr • Artikel • BörsenNEWS.de
Geld/Brief Kurse
Neu ladenBörse | Geld | Vol. | Brief | Vol. | Zeit | Vol. ges. | Kurs |
---|---|---|---|---|---|---|---|
L&S Exchange | 0,18 | 2.770 Stk | 0,19 | 2.770 Stk | 1704442820 5. Jan | 0,18 EUR | |
Nasdaq OTC | 1711671000 01:10 | 694 Tsd. Stk | 0,43 USD | ||||
Baader Bank | 0,45 | 6.397 Stk | 0,49 | 6.383 Stk | 1711653395 28. Mar | 0,47 EUR | |
Frankfurt | 0,43 | 3.000 Stk | 0,50 | 1711641948 28. Mar | 4.425 Stk | 0,42 EUR | |
Tradegate | 0,45 | 6.100 Stk | 0,49 | 5.658 Stk | 1711661181 28. Mar | 27.293 Stk | 0,47 EUR |
Lang & Schwarz | 0,43 | 1.608 Stk | 0,50 | 1.608 Stk | 1711663203 28. Mar | 2.500 Stk | 0,47 EUR |
TTMzero RT | 1711659480 28. Mar | 0,47 EUR | |||||
Berlin | 0,42 | 13.500 Stk | 0,52 | 11.700 Stk | 1711658763 28. Mar | 0,47 EUR | |
Hamburg | 1674458622 23. Jan | 1.042 Stk | 0,62 EUR | ||||
München | 0,45 | 6.100 Stk | 0,49 | 5.658 Stk | 1711609221 28. Mar | 0,33 EUR | |
Stuttgart | 0,44 | 6.100 Stk | 0,49 | 5.658 Stk | 1711650875 28. Mar | 42.250 Stk | 0,49 EUR |
BX Swiss | 0,42 | 34.369 Stk | 0,49 | 34.369 Stk | 1575565200 5. Dec | 1.000 Stk | 1,24 CHF |
Sydney | 1711429838 26. Mar | 0,48 AUD | |||||
Gettex | 0,45 | 6.383 Stk | 0,49 | 6.383 Stk | 1711656812 28. Mar | 29.641 Stk | 0,45 EUR | ges. 802.536 Stk |
Börsennotierung
Marktkapitalisierung in EUR |
---|
227,0 Mio. |
Anzahl der Aktien |
737,1 Mio. |
Termine
30.05.2024 | Quartalsmitteilung |
---|---|
29.07.2024 | Quartalsmitteilung |
02/25 | Quartalsmitteilung |
Grundlegende Daten zur MESOBLAST Aktie
Finanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
---|---|---|---|---|---|---|---|
KUV | 66,68 | 195,71 | 60,94 | 113,97 | - | - | - |
Ergebnis je Aktie (bereinigt) | -0,13 | -0,15 | -0,12 | -0,10 | -0,60 | - | - |
Cashflow | -56,4 Mio. | -0,1 Mrd. | -65,8 Mio. | -63,3 Mio. | - | - | - |
Eigenkapitalquote | 74,88 % | 78,07 % | 75,07 % | 74,97 % | - | - | - |
Verschuldungsgrad | 33,55 | 28,09 | 33,22 | 33,39 | - | - | - |
EBIT | -79,1 Mio. | -0,1 Mrd. | -81,0 Mio. | -69,1 Mio. | - | - | - |
Fundamentaldaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
KCV | -33,34 | -12,23 | -6,77 | -14,25 | - | - | - |
Kurs-Gewinn-Verhältnis (KGV) | -25,65 | -13,05 | -5,08 | -11,40 | -0,94 | - | - |
Bilanzdaten | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
Umsatzerlöse | 32,2 Mio. | 7,5 Mio. | 10,2 Mio. | 7,5 Mio. | - | - | - |
Ergebnis vor Steuern | -87,4 Mio. | -99,6 Mio. | -91,6 Mio. | -82,1 Mio. | - | - | - |
Steuern | -9,4 Mio. | -0,8 Mio. | -0,2 Mio. | -0,2 Mio. | - | - | - |
Info MESOBLAST Aktie
Mesoblast
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.